Women's Health

Cochrane shares her own research findings on how clinician specialty shapes menopause care and highlights gaps in hormone therapy prescribing.

Larkin Larkin, MD, reviews treatment options for VMS, comparing hormone therapy effectiveness with antidepressants and new neurokinin antagonists.

TMS: Harvard's Caroline Mitchell, MD, MPH, questions the direction of genitourinary syndrome research priorities and reflects on FDA's removal of HRT warnings.

Women increasingly seek evidence-based menopause care as awareness grows, yet many still suffer from untreated vasomotor symptoms.

Harvard's Caroline Mitchell, MD, MPH, explains how common OTC products can worsen vulvovaginal symptoms and the importance of a targeted history in GSM care.

Donna Plecha, MD, discusses how AI-powered mammography risk prediction and polygenic risk scores will enable personalized breast cancer screening within the next decade.

Breast imaging expert, Donna Plecha, MD, provides a roadmap for primary care physicians to implement risk assessment tools and high-risk clinic referrals in their practice.

Nearly 40% of perimenopausal women report misdiagnosis as clinicians treat for anxiety and depression without addressing underlying hormonal imbalance.

New research links high ultra-processed food intake to increased risk of precursors for early-onset colorectal cancer in women under 50.

The comprehensive timeline highlights how WHI findings and subsequent research reshaped HRT risk assessment, guidance, and FDA labeling through 2025.

Access, cost, and clinician awareness remain significant barriers to implementing supplemental breast screening, according to Plecha.

Breast imaging expert Donna M. Plecha, MD, explains the FDA's dense breast notification requirement and when to recommend supplemental MRI screening.

Mitchell highlights hormone therapy prescribing for primary care: treatment algorithms, vaginal estrogen safety, and when progestins aren't needed.

TMS 2025: Katrina Wugalter, MA, discusses research showing that age—not menopause stage—drives brain volume decline, and how lifestyle factors can help preserve brain health in midlife women.

Regulatory update aims to align labeling with current evidence on menopausal hormone therapy safety and benefits

TMS 2025: Dr Marla Shapiro doesn't start perimenopausal therapy without an answer to the most important question: "What is your most bothersome symptom?"

Women experience greater CR mortality benefits than men yet have 36% lower enrollment. New AHA statement addresses barriers across the care continuum.

Lisa Larkin, MD, discusses how elinzanetant may change menopause management for women who can’t use hormone therapy and what PCPs need to know.

"If you don't know where your keys are, that's fine." Shapiro's memorable analogy helps distinguish perimenopause brain fog from serious cognitive concerns.

Genitourinary symptoms of menopause often are ignored--by patients and practitioners alike. Primary care clinicians are in a key position to identify, educate, and initiate treatment.

TMS 2025: Donna Plecha, MD, discusses how primary care physicians should approach breast cancer screening in women with dense breasts and use MRI effectively.

TMS 2025: Cochrane explains the impetus behind 2 studies she has authored on the patient- and provider-level factors that influence MHT prescribing.

New research from TMS 2025 covers menopause effects on brain volume, hormone therapy's role in weight loss with GLP-1s, and dense breast screening updates.